Fifty-nine patients with severe chronic heart failure were given pirbuterol, a beta agonist with vasodilator and positive inotropic properties. The acute haemodynamic responses to both single (20 patients) and incremental doses (39 patients) were measured. Pirbuterol increased cardiac index and reduced left ventricular filling pressure and systemic vascular resistance with only small changes in heart rate and blood pressure. Maximal effects were observed at an average of 170 minutes after a single oral dose of pirbuterol. In the incremental dose studies the plasma pirbuterol concentration was found to increase with increasing doses and was related to the magnitude of the haemodynamic response. Pirbuterol was well tolerated, and no drug-related side effects were recorded.
Introduction
Both vasodilator' 2 and positive inotropic drugs3-5 have been shown to produce short-term benefit in chronic heart failure refractory to conventional treatment with digitalis and diuretics. More recent studies have emphasised the advantages of the drug combination.6 7'Hence the ideal drug for treatment would be an oral agent possessing both properties. Pirbuterol is a recently developed sympathomimetic amine structurally similar to salbutamol. In-vitro experiments with animal tissues8 suggest that its principal cardiovascular effect is relaxation of vascular smooth muscle causing vasodilatation (beta2 agonist effect), while in-vivo experiments in animals9 indicate that the drug also exerts a positive inotropic action (beta1 effect). Initial studies in man suggested that pirbuterol may be advantageous in chronic congestive heart failure.10 11 We have studied a large number of patients in three different centres. We investigated the time course of the acute haemodynamic response to two different doses of oral pirbuterol and to at 180, 270, and 360 minutes in any haemodynamic variable except heart rate and systemic vascular resistance (p < 0-01). Group 3 (low-dose incremental studies)-Maximal changes in cardiac index were recorded at 180 or 270 minutes. There was no significant difference between the measurements of any haemodynamic variable at 180 and 270 minutes (table III) . tude of the haemodynamic response to incremental doses of pirbuterol varied with the plasma concentration. Incremental doses caused an increase in the plasma concentration. The results suggest that in most patients 20 mg is sufficient to achieve a maximal haemodynamic effect. Gold and Horowitz,9 studying the action of intravenous pirbuterol in normal dogs, observed a similar response with maximal effects being achieved by an infusion of 2 t±g/kg/min, higher doses having no further effect.
In our single-dose studies the plasma pirbuterol concentrations produced by doses of 10 and 20 mg were similar, as were the haemodynamic responses. The reason for the similar plasma pirbuterol concentrations after different doses is unexplained.
We tried to identify those patients who might show the greatest benefit from pirbuterol. Figure 4 plots the incremental changes in systemic vascular resistance and left ventricular filling pressure against the initial values for all patients in the study. We had expected that patients with the highest systemic vascular resistance and left ventricular filling pressure would show the greatest reduction in these variables. This simple concept was only partly borne out by the results (fig 4) . 
Discusion
This study shows that oral pirbuterol improves cardiac performance in severe chronic heart failure. Cardiac index was increased and systemic vascular resistance and left ventricular filling pressure reduced. These changes were often accompanied by subjective symptomatic improvement. Only small falls in systolic and diastolic blood pressure were observed, and heart rate did not alter except at the highest dose. These results confirm initial studies with pirbuterol in smaller groups of patients.' 11 The haemodynamic effects of pirbuterol resemble those of In clinical studies of patients with heart failure the mechanism by which pirbuterol improves pump performance cannot be determined. Improved cardiac performance may be the consequence of a direct positive inotropic effect or secondary to a vasodilator effect or a combination of these two m anisms. In our patients systolic blood pressure was reduced only by the highest dose of pirbuterol and a small reduction in diastolic blood pressure occurred in all three groups. These changes are consistent with vasodilatation being the dominnt m anism rather than a direct positive inotropic effect.
Experiments in animals" 9 (M L Hayden, unpublished observations) show that pirbuterol has both positive inotropic and vasodilator properties. In isolated preparations of guineapig tracheal muscle' and dogs' hindlegs (M L Hayden) pirbuterol is a potent beta2 agoniist. Gold and Horowitz' showed in dogs that pirbuterol in addition to beta, activity has betaL (cardiac) agonist activity. Moreover, Hayden has confirmed that the drug is a potent inotropic agent in canine heart-lung preparations. Because pirbuterol brought about substantial acute haemodynamic benefits in most patients and is well tolerated and free from major side effects"7 18 53 of these patients have been included in a trial to determine the long-term efficacy of pirbuterol in chronic heart failure.
ONE HUNDRED YEARS AGO
SIR,-Truly he is a happy man -a happy doctor, I should say-who can honestly affirm that he never by his alcoholic prescriptions made a drunkard. For myself, in my earlier days, I was a firm believer in the many supposed virtues of alcoholic compounds. It is about fourteen years ago that the scales were removed from my eyes by the stern reality of facts, and my sole regret now is, that I held out so long against evidence of the most startling kind.
Many years ago I asked a noted drunkard to sign the pledge, when she replied, bitterly, that I was the last man who ought to give her such advice; for it was my own father who had taught her to love the drink. He had prescribed whisky for her in an illness, and she had learned to love it. I did succeed for eighteen months; then she fell, through a publican.
A few months ago, an old lady, a former patient of mine, whom I had not seen for many years, said to me, "Doctor, I 
